Table of Contents Author Guidelines Submit a Manuscript
International Journal of Inflammation
Volume 2012, Article ID 503912, 5 pages
http://dx.doi.org/10.1155/2012/503912
Clinical Study

Intravitreal Dexamethasone in the Management of Delayed-Onset Bleb-Associated Endophthalmitis

1Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
2Department of Ophthalmology, Byers Eye Institute at Stanford, Stanford School of Medicine, Palo Alto, CA 94303, USA

Received 7 August 2011; Accepted 23 October 2011

Academic Editor: Meredith Gregory-Ksander

Copyright © 2012 David J. Jacobs et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose. To report the visual acuity (VA) outcomes and culture results of delayed-onset bleb-associated endophthalmitis (BAE) with and without intravitreal dexamethasone (IVD). Methods. Retrospective nonrandomized comparative case series of BAE at Bascom Palmer Eye Institute between January 1, 1996 and December 31, 2009. Clinical data were compared using the 2-sided Student's t-test for patients who received IVD and patients who did not receive IVD. Results. 70/83 (84%) received IVD, and 13/83 (16%) did not receive IVD. Mean baseline VA was 20/90 in the IVD group and 20/70 in the group that did not receive IVD ( ). Mean presenting VA was 0.9/200 in the IVD group and 1.7/200 in the group that did not receive IVD ( ). Repeat cultures were positive in 2/70 (3%) IVD cases and 1/13 (8%) cases that did not receive IVD ( ). Mean VA at 1 month was 5/200 in the IVD group and 1.8/200 in the group that did not receive IVD, logMARΔ of 0.85 and 1.56, respectively ( ). Mean VA at 3 months was 7/200 in the IVD group and 3/200 in the group that did not receive IVD, logMARΔ of 0.74 and 1.33, respectively ( ). Conclusion. In the current study of BAE, IVD was associated with improved short-term VA outcomes without an increased rate of persistent infection.